Prognostic assessment Variables
Table 1
Figure 1
Thrombosis Age above 60 years
Prior thrombosis
Fibrotic transformation Genetic variables
(ASXL1, IDH2. SRSF2 mutations)
Survival
Age
Leukocytosis
Venous thrombosis
MIPSS-PV
( (Mutation-enhanced)
Clinical (age, leukocytosis)
+
genetic variables (SRSF2 mutations, abnormal
karyotype)
References:
1. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired.
Leukemia. 2009;23(5):834-44.
2. Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep
sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21-30.
